Education
About Us
Working with TipRanks
Follow Us
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
Total Valuation
ENDRA Life Sciences has a market cap or net worth of $5.76M. The enterprise value is $1.27M.
Market Cap$5.76M
Enterprise Value$1.27M
Share Statistics
ENDRA Life Sciences has 1,166,441 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,166,441
Owned by Insiders7.46%
Owned by Institutions1.09%
Financial Efficiency
ENDRA Life Sciences’s return on equity (ROE) is -4.49 and return on invested capital (ROIC) is -274.26%.
Return on Equity (ROE)-4.49
Return on Assets (ROA)-2.58
Return on Invested Capital (ROIC)-274.26%
Return on Capital Employed (ROCE)-2.81
Revenue Per Employee0.00
Profits Per Employee-548.00K
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ENDRA Life Sciences is ―. ENDRA Life Sciences’s PEG ratio is -0.00825.
PE Ratio―
PS Ratio0.00
PB Ratio2.74
Price to Fair Value2.74
Price to FCF-0.95
Price to Operating Cash Flow-0.84
PEG Ratio-0.00825
Income Statement
In the last 12 months, ENDRA Life Sciences had revenue of 0.00 and earned -11.51M in profits. Earnings per share was -10.25.
Revenue0.00
Gross Profit0.00
Operating Income-10.82M
Pretax Income-11.51M
Net Income-11.51M
EBITDA-10.77M
Earnings Per Share (EPS)-10.25
Cash Flow
In the last 12 months, operating cash flow was -5.09M and capital expenditures -17.28K, giving a free cash flow of -5.10M billion.
Operating Cash Flow-5.09M
Free Cash Flow-5.10M
Free Cash Flow per Share-4.38
Dividends & Yields
ENDRA Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change7.86%
50-Day Moving Average5.86
200-Day Moving Average4.83
Relative Strength Index (RSI)45.60
Average Volume (3m)514.97K
Important Dates
ENDRA Life Sciences upcoming earnings date is Mar 26, 2026, TBA (Confirmed).
Last Earnings DateNov 17, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
ENDRA Life Sciences as a current ratio of 5.67, with Debt / Equity ratio of 306.53%
Current Ratio5.67
Quick Ratio5.67
Debt to Market Cap0.00
Net Debt to EBITDA0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ENDRA Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ENDRA Life Sciences EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.59.
EV to Sales0.00
EV to EBITDA-0.41
EV to Free Cash Flow-0.59
EV to Operating Cash Flow-0.59
Balance Sheet
ENDRA Life Sciences has $794.04K in cash and marketable securities with $525.33K in debt, giving a net cash position of $268.71K billion.
Cash & Marketable Securities$794.04K
Total Debt$525.33K
Net Cash$268.71K
Net Cash Per Share$0.23
Tangible Book Value Per Share$2.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ENDRA Life Sciences is $38.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$38.00
Price Target Upside669.23% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast98.86%